This 36-week Phase II randomized, double-blind, placebo-controlled trial evaluated the safety, tolerability, and efficacy of sulforaphane (SF) in 57 children aged 3–12 years with autism spectrum disorder (ASD). Participants received either SF (derived from broccoli seed and sprout extract tablets containing glucoraphanin and active myrosinase, yielding approximately 15 µmol SF
